BML Capital Management, LLC
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 7, 2024), BML Capital Management, LLC reported 27 stock positions worth $136.5 million. Its top holding was iShares 0-3 Month Treasury B (SGOV) at 19.9% of the portfolio, followed by Atea Pharmaceuticals (AVIR, 15.5%) and SS SPDR BB 1-3M T-Bill ETF (BIL, 13.4%). Compared with Q1 2024, it opened 4 new positions, sold out of 7, added to 9 and reduced 3. The biggest buy was a new position in Tectonic Therapeutic (TECX) and the biggest sale an exit from Cyteir Therapeutics (CYTT).
- Most Recent 13F
- Q2 2026
- Location
- ZIONSVILLE, IN
- CIK
- 0001616824
- Portfolio Value
- $136.5M (Q2 2024)
- SEC Filing
- 0001754960-24-000403 ↗ filed Aug 7, 2024
Holdings Value
Holdings 27 stocks · $136.5M
| SGOV iShares 0-3 Month Treasury B | 19.91% | 270,000 | $27.2M | No change |
| AVIR Atea Pharmaceuticals Inc. | 15.45% | 6,375,621 | $21.1M | Add +15.2% |
| BIL SS SPDR BB 1-3M T-Bill ETF | 13.44% | 200,000 | $18.4M | No change |
| ACRS Aclaris Therapeutics Inc. | 10.46% | 12,988,134 | $14.3M | Add +38.2% |
| ADVM Adverum Biotechnologies Inc. | 9.88% | 1,966,000 | $13.5M | Add +136.0% |
| TECX Tectonic Therapeutic Inc. | 5.62% | 466,047 | $7.7M | New |
| RENEO PHARMACEUTICALS INC | 2.96% | 2,672,194 | $4.0M | Add +22.7% |
| TIL Instil Bio Inc. | 2.95% | 391,103 | $4.0M | Add +12.2% |
| ORMP Oramed Pharmaceuticals Inc. | 2.54% | 1,349,038 | $3.5M | Add +59.7% |
| CNTB Connect Biopharma Hldgs Ltd. | 2.27% | 2,043,248 | $3.1M | Reduce -0.9% |
| ATHIRA PHARMA INC | 1.75% | 900,000 | $2.4M | No change |
| VNDA Vanda Pharmaceuticals Inc. | 1.65% | 398,280 | $2.3M | New |
| PMVP PMV Pharmaceuticals Inc. | 1.55% | 1,309,397 | $2.1M | Add +0.2% |
| ASTC Astrotech Corp. | 1.44% | 220,410 | $2.0M | No change |
| MIST Milestone Pharmaceuticals Inc. | 1.07% | 1,102,895 | $1.5M | Add +82.0% |
| DSGN Design Therapeutics Inc. | 1.03% | 421,749 | $1.4M | Reduce -52.0% |
| VRCA Verrica Pharmaceuticals Inc. | 0.96% | 180,000 | $1.3M | No change |
| LENZ Lenz Therapeutics Inc. | 0.81% | 63,916 | $1.1M | No change |
| LSTA Lisata Therapeutics Inc. | 0.72% | 284,669 | $988K | No change |
| IKENA ONCOLOGY INC | 0.71% | 585,114 | $965K | New |
| FORTE BIOSCIENCES INC | 0.69% | 1,761,702 | $946K | No change |
| CALC Calcimedica Inc. | 0.47% | 160,424 | $635K | No change |
| VTGN Vistagen Therapeutics Inc. | 0.38% | 150,000 | $522K | No change |
| ACHL Achilles Therapeutics PL-ADR | 0.37% | 625,174 | $510K | New |
| NXTC Nextcure Inc. | 0.32% | 276,465 | $440K | Reduce -9.8% |
| ALLOVIR INC | 0.32% | 603,086 | $436K | Add +200.8% |
| TLIS Talis Biomedical Corp. | 0.27% | 42,743 | $370K | No change |
Options reported separately and not counted above: WING puts ($3.6M).
Portfolio Sells Q1 2024 → Q2 2024
| CYTT Cyteir Therapeutics Inc. | Sold out | 0.00% | −7.36 |
| CLYM Climb Bio Inc. | Sold out | 0.00% | −4.02 |
| AVROBIO INC | Sold out | 0.00% | −3.43 |
| DSGN Design Therapeutics Inc. | Reduce -52.0% | 1.03% | −1.34 |
| KNTE Kinnate Biopharma Inc. | Sold out | 0.00% | −0.89 |
| ARCA BIOPHARMA INC | Sold out | 0.00% | −0.83 |
| ELVN Enliven Therapeutics Inc. | Sold out | 0.00% | −0.59 |
| QTTB Q32 Bio Inc. | Sold out | 0.00% | −0.28 |
| NXTC Nextcure Inc. | Reduce -9.8% | 0.32% | −0.14 |
| CNTB Connect Biopharma Hldgs Ltd. | Reduce -0.9% | 2.27% | −0.13 |
Portfolio Buys Q1 2024 → Q2 2024
| TECX Tectonic Therapeutic Inc. | New | 5.62% | +5.62 |
| ACRS Aclaris Therapeutics Inc. | Add +38.2% | 10.46% | +2.66 |
| ADVM Adverum Biotechnologies Inc. | Add +136.0% | 9.88% | +1.99 |
| VNDA Vanda Pharmaceuticals Inc. | New | 1.65% | +1.65 |
| ORMP Oramed Pharmaceuticals Inc. | Add +59.7% | 2.54% | +0.89 |
| IKENA ONCOLOGY INC | New | 0.71% | +0.71 |
| RENEO PHARMACEUTICALS INC | Add +22.7% | 2.96% | +0.53 |
| AVIR Atea Pharmaceuticals Inc. | Add +15.2% | 15.45% | +0.48 |
| TIL Instil Bio Inc. | Add +12.2% | 2.95% | +0.43 |
| ACHL Achilles Therapeutics PL-ADR | New | 0.37% | +0.37 |
| MIST Milestone Pharmaceuticals Inc. | Add +82.0% | 1.07% | +0.34 |
| ALLOVIR INC | Add +200.8% | 0.32% | +0.22 |
| PMVP PMV Pharmaceuticals Inc. | Add +0.2% | 1.55% | +0.07 |
Options Activity Q1 2024 → Q2 2024
| WING Wingstop Inc. | put | Reduce -10.8% | 714 | $3.6M |
| ANF Abercrombie & Fitch Co. Class A | put | Sold out | 100 | $470Kbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 15 | $175.1M | ACRS, AVIR, ENGN, KHC, OM |
| Q1 2026 | 15 | $155.4M | ACRS, AVIR, ORMP, TLYS, OM |
| Q4 2025 | 13 | $113.0M | ACRS, AVIR, ORMP, TIL, PMVP |
| Q3 2025 | 19 | $108.7M | ACRS, AVIR, ADVM, TIL, ORMP |
| Q2 2025 | 23 | $130.5M | AVIR, THRD, ACRS, TIL, EPIX |
| Q1 2025 | 27 | $123.6M | AVIR, ACRS, THRD, ADVM, ANTX |
| Q4 2024 | 25 | $161.0M | ACRS, SGOV, AVIR, ADVM, ANTX |
| Q3 2024 | 29 | $169.9M | SGOV, TIL, AVIR, ACRS, BIL |
| Q2 2024 | 27 | $136.5M | SGOV, AVIR, BIL, ACRS, ADVM |
| Q1 2024Amended | 30 | $149.4M | SGOV, AVIR, BIL, ADVM, ACRS |